المؤلفون: SFRISO, PAOLO, GALOZZI, PAOLA, PUNZI, LEONARDO, Priori, Roberta, Valesini, Guido, Rossi, Silvia, Montecucco, Carlo Maurizio, D’Ascanio, Anna, Carli, Linda, Bombardieri, Stefano, Laselva, Gaetana, Iannone, Florenzo, Lapadula, Giovanni, Alivernini, Stefano, Ferraccioli, Gianfranco, Colaci, Michele, Ferri, Clodoveo, Iacono, Daniela, Valentini, Gabriele, Costa, Luisa, Scarpa, Raffaele, Lomonaco, Andrea, Bagnari, Valentina, Govoni, Marcello, Piazza, Ilaria, Adami, Silvano, Ciccia, Francesco, Triolo, Giovanni, Alessandri, Elisa, Cutolo, Maurizio, Cantarini, Luca, Galeazzi, Mauro, Ruscitti, Piero, Giacomelli, Roberto, Caso, Francesco

المساهمون: Sfriso, Paolo, Priori, Roberta, Valesini, Guido, Rossi, Silvia, Montecucco, Carlo Maurizio, D’Ascanio, Anna, Carli, Linda, Bombardieri, Stefano, Laselva, Gaetana, Iannone, Florenzo, Lapadula, Giovanni, Alivernini, Stefano, Ferraccioli, Gianfranco, Colaci, Michele, Ferri, Clodoveo, Iacono, Daniela, Valentini, Gabriele, Costa, Luisa, Scarpa, Raffaele, Lomonaco, Andrea, Bagnari, Valentina, Govoni, Marcello, Piazza, Ilaria, Adami, Silvano, Ciccia, Francesco, Triolo, Giovanni, Alessandri, Elisa, Cutolo, Maurizio, Cantarini, Luca, Galeazzi, Mauro, Ruscitti, Piero, Giacomelli, Roberto, Caso, Francesco, Galozzi, Paola, Punzi, Leonardo

مصطلحات موضوعية: Adult-onset Still’s disease, Biologic drug, Clinical presentation, Laboratory finding, Retrospective study, Rheumatology

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27207567; info:eu-repo/semantics/altIdentifier/wos/WOS:000379010900004; volume:35; issue:7; firstpage:1683; lastpage:1689; numberofpages:7; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/11577/3192014Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84969801181; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-016-3308-8Test
http://hdl.handle.net/11577/3192014Test

المؤلفون: Sfriso, Paolo, PRIORI, ROBERTA, VALESINI, Guido, Rossi, Silvia, Montecucco, Carlo Maurizio, D’Ascanio, Anna, Carli, Linda, Bombardieri, Stefano, Laselva, Gaetana, Iannone, Florenzo, Lapadula, Giovanni, Alivernini, Stefano, Ferraccioli, Gianfranco, Colaci, Michele, Ferri, Clodoveo, Iacono, Daniela, Valentini, Gabriele, Costa, Luisa, Scarpa, Raffaele, Lomonaco, Andrea, Bagnari, Valentina, Govoni, Marcello, Piazza, Ilaria, Adami, Silvano, Ciccia, Francesco, Triolo, Giovanni, Alessandri, Elisa, Cutolo, Maurizio, Cantarini, Luca, Galeazzi, Mauro, Ruscitti, Piero, Giacomelli, Roberto, Caso, Francesco, Galozzi, Paola, Punzi, Leonardo

المساهمون: Sfriso, Paolo, Priori, Roberta, Valesini, Guido, Rossi, Silvia, Montecucco, Carlo Maurizio, D’Ascanio, Anna, Carli, Linda, Bombardieri, Stefano, Laselva, Gaetana, Iannone, Florenzo, Lapadula, Giovanni, Alivernini, Stefano, Ferraccioli, Gianfranco, Colaci, Michele, Ferri, Clodoveo, Iacono, Daniela, Valentini, Gabriele, Costa, Luisa, Scarpa, Raffaele, Lomonaco, Andrea, Bagnari, Valentina, Govoni, Marcello, Piazza, Ilaria, Adami, Silvano, Ciccia, Francesco, Triolo, Giovanni, Alessandri, Elisa, Cutolo, Maurizio, Cantarini, Luca, Galeazzi, Mauro, Ruscitti, Piero, Giacomelli, Roberto, Caso, Francesco, Galozzi, Paola, Punzi, Leonardo

مصطلحات موضوعية: Adult-onset Still’s disease, Biologic drug, Clinical presentation, Laboratory finding, Retrospective study, Rheumatology, Medicine (all)

الوصف: Adult-onset Still's disease (AOSD) is a systemic inflammatory condition of unknown aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a multicentric data collection to characterize the clinical phenotype of Italian patients with AOSD. Data from 245 subjects diagnosed with AOSD were collected by 15 centres between March and May 2013. The diagnosis was made following Yamaguchi's criteria. Data regarding clinical manifestations, laboratory features, disease course and treatments were reported and compared with those presented in other published series of different ethnicity. The most frequent features were the following: arthritis (93 %), pyrexia (92.6 %), leukocytosis (89 %), negative ANA (90.4 %) and neutrophilia (82 %). As compared to other North American, North European, Middle Eastern and Far Eastern cohorts, Italian data show differences in clinical and laboratory findings. Regarding the treatments, in 21.9 % of cases, corticosteroids and traditional DMARDs have not been able to control the disease while biologics have been shown to be effective in 48 to 58 patients. This retrospective work summarizes the largest Italian multicentre series of AOSD patients and presents clinical and laboratory features that appear to be influenced by the ethnicity of the affected subjects.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27207567; info:eu-repo/semantics/altIdentifier/wos/WOS:000379010900004; volume:35; issue:7; firstpage:1683; lastpage:1689; numberofpages:7; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/11573/885115Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84969801181; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-016-3308-8Test
http://hdl.handle.net/11573/885115Test

المؤلفون: Ferraccioli, Gianfranco, Gremese, Elisa

المساهمون: Iannone, Florenzo, Sinigaglia, Lugi, Favalli, Ennio Giulio, Sarzi Puttini, Piercarlo, Atzeni, Fabiola, Caporali, Roberto, Codullo, Veronica, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, Lapadula, Giovanni

مصطلحات موضوعية: Drug survival, GISEA, HAQ, LORHEN, Rheumatology, Settore MED/16 - REUMATOLOGIA

الوصف: The purpose of the study was to estimate the clinical profile of naïve biological patients with rheumatoid arthritis (RA) starting adalimumab through 3-year calendar periods and their clinical outcomes such as drug survival and global clinical disease control (GCDC). RA patients starting adalimumab as first biological drug between 2003 and 2012 were subdivided in 3-year calendar periods. Survival on therapy was estimated using the Kaplan-Meier analysis. One and 2-year clinical response was assessed by calculating percentage of patients attaining GCDC (28-joint Disease Activity Score (DAS28) ≤ 2.6 + Health Assessment Questionnaire (HAQ) ≤ 0.5), low disease activity (DAS28 ≤ 3.2), remission (DAS28 ≤ 2.6) and good European League Against Rheumatism (EULAR) response. Multivariate regression models were used to assess baseline predictors of drug discontinuation or achievement of clinical remission. We recruited 1695 RA patients. Overall drug persistence at 3 years was 40.6 %, while the global rate of nonswitching patients was 54.7 %. Compared to 2003–2005, initiators in more recent years had a significantly lower 3-year crude drug retention rate (log rank, p < 0.0001) and a significantly higher rate of switching to alternative biologics (log rank, p < 0.0001). No difference in adverse events or effectiveness rate among the calendar periods was found. A substantial proportion of patients (up to 27 %) achieved GCDC at 2 years, regardless of the calendar period. In real-life setting, RA patients starting adalimumab in more recent years had a higher rate of drug discontinuation not related to ineffectiveness or side effects but to switching, probably due to a wider availability of biologics. A meaningful proportion of patients attained GCDC without any difference across calendar periods.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27418051; info:eu-repo/semantics/altIdentifier/wos/WOS:000386362000003; volume:35; issue:11; firstpage:2649; lastpage:2656; numberofpages:8; issueyear:2016; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/10807/94034Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84978828157; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-016-3349-zTest
http://hdl.handle.net/10807/94034Test

المؤلفون: Gremese, Elisa, Ferraccioli, Gianfranco

المساهمون: Iannone, Florenzo, Gremese, Elisa, Ferraccioli, Gianfranco, Lapadula, Giovanni

مصطلحات موضوعية: Adalimumab, Antirheumatic Agent, Arthritis, Rheumatoid, Chemical and Drug Induced Liver Injury, Etanercept, Female, Hepatitis C, Chronic, Human, Male, Rheumatology, Settore MED/16 - REUMATOLOGIA

الوصف: Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study. [Clin Rheumatol. 2015]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26113173; info:eu-repo/semantics/altIdentifier/wos/WOS:000372429000043; volume:35; issue:3; firstpage:839; lastpage:840; numberofpages:2; issueyear:2016; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/10807/94108Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84960437525; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-015-2997-8Test
http://hdl.handle.net/10807/94108Test

المؤلفون: Alivernini, Stefano, Ferraccioli, Gianfranco

المساهمون: Sfriso, Paolo, Priori, Roberta, Valesini, Guido, Rossi, Silvia, Montecucco, Carlo Maurizio, D’Ascanio, Anna, Carli, Linda, Bombardieri, Stefano, Laselva, Gaetana, Iannone, Florenzo, Lapadula, Giovanni, Alivernini, Stefano, Ferraccioli, Gianfranco, Colaci, Michele, Ferri, Clodoveo, Iacono, Daniela, Valentini, Gabriele, Costa, Luisa, Scarpa, Raffaele, Lomonaco, Andrea, Bagnari, Valentina, Govoni, Marcello, Piazza, Ilaria, Adami, Silvano, Ciccia, Francesco, Triolo, Giovanni, Alessandri, Elisa, Cutolo, Maurizio, Cantarini, Luca, Galeazzi, Mauro, Ruscitti, Piero, Giacomelli, Roberto, Caso, Francesco, Galozzi, Paola, Punzi, Leonardo

مصطلحات موضوعية: Adult-onset Still’s disease, Biologic drug, Clinical presentation, Laboratory finding, Retrospective study, Rheumatology, Settore MED/16 - REUMATOLOGIA

الوصف: Adult-onset Still’s disease (AOSD) is a systemic inflammatory condition of unknown aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a multicentric data collection to characterize the clinical phenotype of Italian patients with AOSD. Data from 245 subjects diagnosed with AOSD were collected by 15 centres between March and May 2013. The diagnosis was made following Yamaguchi’s criteria. Data regarding clinical manifestations, laboratory features, disease course and treatments were reported and compared with those presented in other published series of different ethnicity. The most frequent features were the following: arthritis (93 %), pyrexia (92.6 %), leukocytosis (89 %), negative ANA (90.4 %) and neutrophilia (82 %). As compared to other North American, North European, Middle Eastern and Far Eastern cohorts, Italian data show differences in clinical and laboratory findings. Regarding the treatments, in 21.9 % of cases, corticosteroids and traditional DMARDs have not been able to control the disease while biologics have been shown to be effective in 48 to 58 patients. This retrospective work summarizes the largest Italian multicentre series of AOSD patients and presents clinical and laboratory features that appear to be influenced by the ethnicity of the affected subjects.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27207567; info:eu-repo/semantics/altIdentifier/wos/WOS:000379010900004; volume:35; issue:7; firstpage:1683; lastpage:1689; numberofpages:7; issueyear:2016; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/10807/94039Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84969801181; link.springer.de/link/service/journals/10067/index.htm

الإتاحة: https://doi.org/10.1007/s10067-016-3308-8Test
http://hdl.handle.net/10807/94039Test

المؤلفون: Iannone, Florenzo, Gremese, Elisa, Gallo, Gaia, Sarzi-Puttini, Piercarlo, Botsios, Costantino, Trotta, Francesco, Gasperini, Stefania, Galeazzi, Mauro, Adami, Silvano, Cantini, Fabrizio, Sebastiani, Marco, Gorla, Roberto, Marchesoni, Antonio, Giardina, Annarita, Foti, Rosario, Mele, Angiola, Bruschi, Eleonora, Bagnato, Gianluca, Erre, Gian Luca, Lapadula, Giovanni, Scioscia, Crescenzio, Fedele, Anna Laura, Ferraccioli, Gianfranco, Atzeni, Fabiola, Bongiovanni, Sara, Punzi, Leonardo, Bernardi, Livio, Bagnari, Valentina, Govoni, Marcello, Grassi, Walter, Salaffi, Fausto, Manganelli, Stefania, Frati, Elena, Carletto, Antonio, Caimmi, Cristian, Palloni, Alice, Niccoli, Laura, Ferri, Clodoveo, Favalli, Ennio Giulio, Triolo, Giovanni, Di Gangi, Marcella

المساهمون: F. Iannone, E. Gremese, G. Gallo, P. Sarzi-Puttini, C. Botsio, F. Trotta, S. Gasperini, M. Galeazzi, S. Adami, F. Cantini, M. Sebastiani, R. Gorla, A. Marchesoni, A. Giardina, R. Foti, A. Mele, E. Bruschi, G. Bagnato, G.L. Erre, G. Lapadula, C. Scioscia, A.L. Fedele, G. Ferraccioli, F. Atzeni, S. Bongiovanni, L. Punzi, L. Bernardi, V. Bagnari, M. Govoni, W. Grassi, F. Salaffi, S. Manganelli, E. Frati, A. Carletto, C. Caimmi, A. Palloni, L. Niccoli, C. Ferri, E.G. Favalli, G. Triolo, M. Di Gangi

مصطلحات موضوعية: DAS28, Disease remission, GISEA, HAQ, TNF-alpha inhibitors, Settore MED/16 - Reumatologia

الوصف: The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis (RA) patients with moderate or severe disease activity. We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides (GISEA) to investigate the rate of disease remission and functional improvement, based on the 28-Joint Disease Activity Score (DAS28) and the (Health Assessment Questionnaire (HAQ) score in RA patients with moderate or severe disease activity beginning etanercept therapy. Disease was defined as severe (H-RA) withDAS28 ≥5.1 and moderate (M-RA) with DAS28 =3.2 to 5.1 at baseline. Patients were considered in remission if DAS28 was ≤2.6, and HAQ ≤0.5 defined normal function. We enrolled 953 RA patients, 320 with M-RA and 633 H-RA. Age and disease duration were similar in the two cohorts, but H-RA patients had significantly more comorbidities (p <0.01) and took significantly more disease-modifying antirheumatic drugs (p <0.001) than MRA patients. After 1 year, the percentage of patients achieving disease remission and normal function (DAS28 ≤2.6 plus HAQ ≤0.5) was higher in M-RA (21.4 %) than in H-RA patients (14.8%, p =0.007), regardless of the disease duration. Additionally, female gender (p =0.006) and H-RA class (p = 0.002) negatively predicted disease remission at 1 year. However, the drug survival rate did not differ between the two subsets. This study confirms that etanercept was effective in the treatment of active RA, but best response, in terms of disease remission and normal function ability, was greater and easier to attain in M-RA patients. These findings may aid clinicians to choose the best strategy to treat RA.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23954923; info:eu-repo/semantics/altIdentifier/wos/WOS:000329941600005; volume:33; issue:1; firstpage:31; lastpage:37; numberofpages:7; journal:CLINICAL RHEUMATOLOGY; http://hdl.handle.net/2434/643245Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84897631607

الإتاحة: https://doi.org/10.1007/s10067-013-2348-6Test
http://hdl.handle.net/2434/643245Test